Azacytidine treatment after discontinuation of immunosuppressants in patients with myelodysplastic syndrome and relapse after allo-SCT at a single center

Bone Marrow Transplantation

Volumn 45, Issue 8, 2010, Pages 1375-1376

  Kim, S Y ^a   Cho, S G ^a   Cho, B S ^a   Kim, M S ^a   Eom, K S ^a   Kim, Y J ^a   Kim, H J ^a   Lee, S ^a   Min, C K ^a   Kim, D W ^a   Lee, J W ^a   Min, W S ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; IMMUNOSUPPRESSIVE AGENT;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER SURVIVAL; DISEASE DURATION; DONOR LYMPHOCYTE INFUSION; DRUG RESPONSE; DRUG WITHDRAWAL; GRAFT VERSUS HOST REACTION; HUMAN; KARYOTYPE; LETTER; LEUKEMIA RELAPSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; THROMBOCYTOPENIA;

ADULT; AZACITIDINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PILOT PROJECTS; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77955586814     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.355     Document Type: Letter

References (9)

1. Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2007; 40:1027-1032.
2. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
3. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20: 405-412.
4. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440. (Pubitemid 34525728)
5. Santourlidis S, Trompeter HI, Weinhold S, Eisermann B, Meyer KL, Wernet P et al. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J Immunol 2002; 169: 4253-4261.
6. Pinto A, Maio M, Attadia V, Zappacosta S, Cimino R. Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2'-deoxycytidine. Lancet 1984; 2: 867-868.
7. Reitz Jr MS, Mann DL, Eiden M, Trainor CD, Clarke MF. DNA methylation and expression of HLA-DR alpha. Mol Cell Biol 1984; 4: 890-897.
8. Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y et al. De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immuno- therapy in a murine tumor model. Cancer Res 2006; 66: 1105-1113.
9. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425.